Market Research Logo

Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global

Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global

Market for Hepatitis C drugs has grown with a phenomenal rate of more than US$ 13 Billion, in the year 2014 compared to 2013. In the last two years a couple of new drugs have been introduced in the market which has become a huge success and they have captured maximum market share of the Hepatitis C market. Gilead currently dominates the multi-billion dollar Hepatitis C market, but AbbVie has been trying to increase its market share since U.S. regulators approved the marketing of its Viekira Pak. Drug makers are already focusing on introducing new drugs in the market as several drugs are standing in the pipeline. Hepatitis C Drugs is anticipated to be a rosy market for future period.

This is 3rd edition report on Hepatitis C Drugs Industry by Renub Research. Report titled “Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global” provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 87 page report with 18 Figures and 1 Table studies the Hepatitis C Drug Market Landscape.

1. Hepatitis C Drugs Market & Forecast (Chapter 2)
2. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3)
3. Hepatitis C – Pipeline Drugs Sales & Forecast (Chapter 4)
4. Hepatitis C Deals & Acquisitions (Chapter 5)
5. Hepatitis C – Company Wise Clinical Trial Analysis (Chapter 6)

Hepatitis C – Approved Drugs Sales & Forecast (To 2020) (Chapter No. 3)

1. Pegasys
2. Pegintron
3. Incivek
4. Victrelis
5. Olysio
6. Sovaldi/Harvoni
7. HCV Franchise
8. Viekira Pak

Hepatitis C – Pipeline Drugs Sales Forecast (To 2020) (Chapter No. 4)

1. Drug A (Merck & Co. Inc.)
2. Drug B (Merck & Co. Inc.)
3. Drug C (Bristol-Myers Squibb)

Hepatitis C – Company Wise Clinical Trial Analysis (Chapter No.5)

1. AbbVie
2. Bristol-Myers Squibb (BMS)
3. Gilead Sciences
4. Merck & Co. Inc.
5. Tibotec/Janssen Therapeutics

Data Sources

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.

Primary sources include industry surveys and telephone interviews with industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.


  • Executive Summary
  • Hepatitis C Drugs - Market & Forecast
  • Hepatitis C - Approved Drugs Sales & Forecast
    • Pegasys Sales & Forecast
    • Pegintron Sales & Forecast
    • Incivek Sales
    • Victrelis Sales & Forecast
    • Olysio Sales & Forecast
    • Sovaldi / Harvoni Sales & Forecast
    • HCV Franchise Sales & Forecast
    • Viekira Pak Sales & Forecast
  • Hepatitis C - Pipeline Drugs Sales Forecast
    • Drug A of (Merck & Co. Inc.)
    • Drug B of (Merck & Co. Inc.)
    • Drug C of (Bristol-Myers Squibb)
  • Hepatitis C - Deals & Acquisitions
    • Table Hepatitis C - Deals & Acquisitions in the anti-HCV Drug Space, 2004 - 2012
  • Hepatitis C - Company Wise Clinical Trials Analysis
    • AbbVie - Clinical Trials
      • Phase III
      • Phase II
      • Phase I
    • Bristol-Myers Squibb (BMS) - Clinical Trials
      • Phase III
      • Phase II
    • Gilead Sciences - Clinical Trials
      • Phase II
    • Merck & Co. Inc. - Clinical Trials
      • Phase IV
      • Phase III
      • Phase II
      • Phase I
    • Tibotec / Janssen Therapeutics - Clinical Trials
      • Phase IV
      • Phase III
      • Phase II
      • Phase I

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report